BridgeBio Oncology Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
16.8%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$2.21next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Updated Clinical Data Readouts for BBO-8520, BBO-11818, and BBO-10203 | 31 Dec 2026 |
| Q3 2026 Financial Results and Corporate Update | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
BBO-8520 Objective Response Rate (ORR) in KRAS G12C Mutant NSCLC Quarterly65.0%Target: Maintain or exceed 60% ORR in expanded combination cohorts
BBO-8520 6-Month Progression-Free Survival (PFS) Rate Quarterly68.0%Target: Maintain >65% PFS in monotherapy and combination trials
BBO-11818 Pan-KRAS Monotherapy Tumor Reduction in PDAC Quarterly0.6Target: Demonstrate consistent tumor shrinkage and confirmed PRs in expanded cohorts
BBO-10203 Hyperglycemia Incidence Rate (Grade >= 3 TRAEs) Quarterly0.0%Target: 0% incidence of treatment-related hyperglycemia
Watch Items
- BBO-8520 Combination Data with PembrolizumabTrigger: Efficacy and safety readouts in the second half of 2026Action: Evaluate liver toxicity profile (transaminase elevations) and ORR compared to historical pembrolizumab monotherapy benchmarks.
- BBO-11818 Dose Escalation and ExpansionTrigger: Updated monotherapy and combination safety/efficacy data in the second half of 2026Action: Monitor for potential pan-KRAS class toxicities (e.g., gastrointestinal or skin toxicities) at higher therapeutic dose levels.
- BBO-10203 Internal Combination CohortsTrigger: Initiation and early safety readouts of combinations with BBO-8520 and BBO-11818 in late 2026Action: Assess the tolerability of concurrent MAPK and PI3Kα pathway inhibition without inducing cumulative toxicities.
- Cash Burn Rate and RunwayTrigger: Quarterly R&D expenses exceeding $45 millionAction: Re-evaluate clinical trial prioritization to ensure the cash runway remains sufficient to fund operations into 2028.
Research as of 19 Jun 2026